Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh ( (AU:RMD) ) has shared an announcement.
ResMed Inc. has disclosed that company officer Brett Sandercock plans to sell 1,000 common shares on or around 2 January 2026 through Fidelity Brokerage Services LLC, with an aggregate market value of about $241,750, under a previously adopted Rule 10b5-1 trading plan dated 19 February 2025. The filing also notes that Sandercock, who acquired these shares as restricted stock vesting in November 2022 as part of his compensation, sold a total of 4,000 ResMed shares in the prior three months for gross proceeds of nearly $987,000, providing investors with additional visibility into planned insider share disposals and trading activity but representing a small fraction of the company’s roughly 146 million shares outstanding.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$45.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
More about Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
ResMed Inc. is a U.S.-based medical technology company focused on developing and manufacturing devices and software solutions for the diagnosis, treatment and long-term management of sleep-disordered breathing and other chronic respiratory conditions. Its primary products include continuous positive airway pressure (CPAP) devices, ventilators and related cloud-connected platforms, with a significant presence in both hospital and home-care markets worldwide.
Average Trading Volume: 1,176,152
Technical Sentiment Signal: Buy
Current Market Cap: A$53.49B
For detailed information about RMD stock, go to TipRanks’ Stock Analysis page.